Fortitude Biomedicines closed a $13 million seed round to develop GLUE‑DACs—antibody‑drug conjugates that use molecular glue degraders as payloads—and advance a lead preclinical immune‑cell targeting biologic. The company, spun out of Baylor College of Medicine research led by Jin Wang, will use proceeds to power GLUE‑DAC discovery and preclinical validation. Founders include academics Jin Wang and Michael DeBakey, plus entrepreneur CEO Jesse Chen; investors include K2 Bio Partners and Shanghai Healthcare Angel Capital. Fortitude says GLUE‑DAC aims to combine ADC targeting precision with catalytic targeted protein degradation to overcome ADC resistance mechanisms. The seed raise enters a competitive space where molecular glues have prompted major pharma alliances and acquisitions. Fortitude’s proposition—integrating degraders into ADC platforms—could expand payload modalities if preclinical efficacy and safety support translation.